Nutraceuticals CDMO Market Assessment, By Dosage Form [Tablets and Capsules, Powder, Others], By Service [Product Formulation and Development, Manufacturing and Packaging, Research and Development, Regulatory Compliance, Others], By Company Size [Small Co

Nutraceuticals CDMO Market Assessment, By Dosage Form [Tablets and Capsules, Powder, Others], By Service [Product Formulation and Development, Manufacturing and Packaging, Research and Development, Regulatory Compliance, Others], By Company Size [Small Companies, Mid-sized Companies, Large Companies], By Region, Opportunities and Forecast, 2017-2031F

Global 3D cell culture market is projected to witness a CAGR of 11.61% during the forecast period 2024-2031, growing from USD 1.38 billion in 2023 to USD 3.31 billion in 2031.

The several key drivers of the 3D cell culture market are the advancement in the technologies that increase the accuracy and reliability of 3D models, improved funding through research and development, and an increasing demand for personalized medicine. Also, there is a shift toward alternative testing methods, especially to reduce animal model dependencies and the rising need for organ transplantation and tissue engineering. Strategic partnerships and collaborations lead to market growth through innovation and increased access to the latest technologies.

3D cell culture is one of the pioneering cell culture techniques that allows cells to grow in a condition more reminiscent of their native structures in living tissues. Unlike traditional 2D cultures, 3D cell cultures provide deeper insight into cell behavior, growth, and interactions, resembling in-vivo conditions. The technique holds a promising position in drug discovery, oncological research, and regenerative therapy as it provides predictability of human responses to treatments. Increasing demand for more physiologically relevant models combined with advances in biotechnological innovations has led to quick expansion in the 3D cell culture market, making it crucial in the life sciences domain.

For instance, in April 2024, Sartorius AG partnered with TheWell Bioscience Inc. to develop hydrogel and bioink solutions for drug discovery workflows of 3D cell models. Sartorius' lab division is also going to be strengthened through the distribution of TheWell Bioscience's products and investment in a minority shareholding. The company aims to facilitate improvement from a model based on animal sources to one that is human-relevant in the organoid models, thereby allowing better predictions in drug discovery. This synergy will further accelerate market growth with TheWell Bioscience's cell imaging bioanalytical lab instruments and solutions to reinforce Sartorius' innovative edge.

Expanding Role of 3D Cell Culture

The growing roles of the 3D cell culture market are largely propelling its growth. Pharmaceutical and biotech companies are increasingly employing such cultures in drug discovery and development, having found them to be more predictive of human responses than conventional models. Advanced research into tissue engineering and regenerative medicine by academic institutions also enhances market growth by incorporating 3D cell cultures. The increased ethical scrutiny of experiments, such that results can be accomplished with 3D cell models rather than involving animals, is driving the market increase. These expanded applications, along with efficiencies of collaboration between different sectors, have inspired innovation and expanded the 3D cell cultures to broaden research and clinical applications.

For instance, PHC Holdings Corporation's Biomedical Division launched LiCellMo, a live cell metabolic analyzer, in Japan and North America in September and October 2024, respectively. This allows researchers to observe real-time changes in metabolism in culture. The goal is to attain a panoramic view of the activity for potential applications in cell and gene therapies (CGT) research. The device uses PHC's proprietary high-precision in-line monitoring technology that allows continuous measurement of cellular metabolites in a culture medium without disrupting experiments.

Advancements in 3D Cell Culture Techniques Drive Market Growth

Advancements in 3D cell culture technologies, especially microfluidics, have transformed market growth. High accuracy and scalability of cell models through a controlled flow of nutrients, oxygen, and waste in a microfluidic system that closely mimics physiological conditions in real-time. This technique supports the creation of highly accurate tissue and organ models, which are ideal for testing drug toxicity and applications of personalized medicine. By allowing high-throughput screening and reducing reagent usage, microfluidics lowers operational costs and improves experimental reproducibility, attracting significant investment and research interest. As a result, microfluidics is expanding the applications and value of 3D cell culture systems. For instance, in September 2024, InSphero Inc. entered into a distribution agreement with Darwin Microfluidics to expand the reach of their 3D in vitro products in the European Union. InSphero products will be easily accessible to EU researchers because of its partnership with Darwin Microfluidics, a startup developing advanced microfluidic solutions. This deal reflects the fast uptake of microfluidics and technological advancement in the market, increasing growth and innovation in 3D cell culture applications.

Investment in Research Fueling the Market Growth

Strategic investments into the 3D cell culture market have expanded its growth as it encourages innovation and technology development. More venture capital and research grants are being allocated to support the establishment of complex 3D models that are more accurate than conventional 2D cultures with enhanced predictive values. Investments of this nature are accelerating partnerships and collaborations among companies, academics, and research organizations, further accelerating the commercialization of new technologies. In addition to this, strategic investments have increased fields of applications for 3D cell cultures in drug discovery, regenerative medicine, and personalized therapy. Similarly, financial investment enhances manufacturing capacity and scale-up ability to make 3D cell cultures available for research and clinics. Thus, strategic investments help to build up the market by making 3D cell cultures innovate and expanding their utility.

For instance, in September 2024, Carl Zeiss AG invested strategically in the life science startup InSphero AG to accelerate innovation in 3D cell culture research. InSphero AG focuses on the development of 3D spheroid and cell-based assays for pharmaceutical drug discovery and safety testing. The received funding will be used to commercialize its cryo-preservation technology and further speed up the growth and scalability of the company. This funding was shared between internal and external investors, including ZEISS Ventures.

Dominance of Scaffold-Based Type in 3D Cell Culture

The scaffold-based segment dominated the market of 3D cell culture mainly because it can closely mimic the natural extracellular matrix and provides a more realistic environment for cells to grow. This stimulates cell-cell and cell-matrix interactions, thus ensuring better cell differentiation as well as functionality. Scaffold-based systems play an important role in establishing intricate tissue patterns, which are crucial for advanced drug testing as well as regenerative medicine applications. These also keep longer-term cultures and resemble the vivo environment more closely than traditional 2D cultures. These features make scaffold-based models more valuable for research and clinical applications, giving them a major market share. The preference to use scaffold-based 3D cell cultures over others by researchers shows the importance of these types in getting more accurate experimental and reliable results.

For instance, in August 2024, CytoNest Inc., a University of Georgia startup, launched its first commercial product, the CytoSurge 3D fiber scaffold. This is a next-generation system in cell manufacturing and tissue engineering and supports applications in cell research, biopharmaceuticals, cell therapies, and cultured meat and seafood. Advanced scaffolding technologies, such as new developments in the CytoSurge 3D fiber scaffold, drive market growth based on optimization through various applications in research and industrial use.

North America Dominates 3D Cell Culture Market Share

North America dominates the global 3D cell culture market due to high R&D investments in the region, well-established biotechnology and pharmaceutical infrastructure, and a strong regulatory framework that supports advanced research. Many world-leading biopharma companies are headquartered in the US, and their research institutions are very much actively involved in stem cell research, cancer biology, and regenerative medicine, where 3D cell cultures are important. Strong government funding is another driving force for innovation in the region, especially from bodies such as the NIH. Due to the biopharmaceutical hub in the region, there is access to advanced technologies that drive the rapid adoption and integration of 3D cell culture techniques into biomedical research.

In July 2023, 3D BioFibR Inc. raised over USD 3.2 million in seed financing. Funds that will be utilized in capacity expansion efforts via climate-controlled biomanufacturing and bringing high-quality collagen fiber products to market. Such products offer an excellent prospect for use in 3D cell culture and tissue engineering applications. This momentum is expected to be realized in North America as companies line up their upgraded capabilities within the region to propel growth in the market further.

Future Market Scenario (2024-2031F)

Advancements in technology coupled with an increasing number of applications for drug discovery, personalized medicine, and regenerative therapies would define the outlook of this market over the near future. Improved modeling capabilities, responsible research practices, and increased collaborations will likely fuel growth in this market, making 3D cell cultures an essential tool for new biomedical research and clinical developments.

Moreover, company expansions boost market growth due to improved manufacturing capacity and increased access to cutting-edge technologies. In July 2023, the company Inventia Life Science Pty Ltd. expanded its operations to India through a partnership with Biotron Healthcare PVT Ltd. to distribute RASTRUM. By making possible cancer, neurodegenerative disease, and fibrotic condition research through advanced cellular models, RASTRUM serves as a backbone in drug discovery, disease modeling, and basic biological research by focusing on physiologically meaningful models of disease.

Key Players Landscape and Outlook

Prominent players in the 3D cell culture market drive growth through strategic partnerships, new product launches, and expansion of the distribution network. Such strategies help enhance market presence, stimulate innovation, and provide greater access to leading-edge cell culture technologies.

In August 2023, InSphero AG collaborated with Advanced BioMatrix, Inc., an industry leader in 3D life science applications to expand the scope of applications in 3D cell culture into scaffold-based models. Under this partnership, InSphero's Akura Plate Technology will be distributed by Advanced BioMatrix in the U.S. It will enhance its market penetration and strengthen its position in this market.

In August 2023, Sartorius AG launched an integrated bioreactor system in collaboration with Repligen Corporation that enables customers to integrate Repligen's XCell ATF upstream intensification technology with Sartorius' Biostat STR bioreactor. The innovation simplifies intensified seed train and N perfusion processes for biopharmaceutical manufacturers. This launch further highlights the market leadership position of Sartorius in process intensification and upstream processing technologies and strengthens its overall market position.